OVERVIEW

Red Light, Yellow Light, Green Light: The Art and Science of Treatment Decision-Making in Patients with HBV is organized by CME Outfitters, LLC and will be held from Dec 14, 2018 - Dec 14, 2019.

Target Audience:
Gastroenterologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with HBV.

Credit Information
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs)

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Statement of Need:
It is estimated that approximately 850,000 individuals in the United States are chronically infected with chronic hepatitis B virus (HBV); however, these numbers may be grossly underestimated because of suboptimal screening practices. The CDC estimated that for every reported case of HBV, there are 6.5 new infections that go unreported. Although chronic HBV is not yet curable, timely and effective treatment can reduce the chance of an individual progressing to liver disease, hepatocellular cancer, and ultimately death.

The Action Plan for the Prevention Care & Treatment of Viral Hepatitis hopes to increase linkage to care by supporting an integrated care model and recommending that HBV testing, care, and treatment services be integrated into primary care, enabling providers to take a holistic approach to meet individual needs.

This CME Outfitters interactive infographic addresses questions about serologic results, monitoring viral loads, and the AASLD recommendations from our expert facility.

Learning Objectives:
At the end of this CE activity, participants should be able to:
• Evaluate serology results in patients screened for HBV to determine phase of disease and candidacy for treatment.
• Initiate antiviral therapy in patients with immune-active chronic HBV aligned to established AASLD/EASL recommendations.

The following learning objectives pertain only to those requesting CNE or CPE credit:
• Discuss serology results in patients screened for HBV in order to determine phase of disease and candidacy for treatment.
• Describe antiviral therapy in patients with immune-active chronic HBV aligned to established AASLD/EASL recommendations.

Additional details will be posted as soon as they are available.